Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer

NCT02025712 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Hormone Receptor Positive Malignant Neoplasm of Breast

Interventions

DRUG: Exemestane
DRUG: Everolimus

Sponsor

Organisation for Oncology and Translational Research